实用器官移植电子杂志
實用器官移植電子雜誌
실용기관이식전자잡지
Practical Journal of Organ Transplantation (Electronic Version)
2014年
6期
356-359
,共4页
陈栋%魏来%蒋继贫%杨军%曹志新%陈知水
陳棟%魏來%蔣繼貧%楊軍%曹誌新%陳知水
진동%위래%장계빈%양군%조지신%진지수
肝胰十二指肠联合移植%疗效
肝胰十二指腸聯閤移植%療效
간이십이지장연합이식%료효
Liver-pancreas-duodenum transplantation%Effects
目的探讨肝胰十二指肠联合移植的适应证和治疗效果。方法总结分析本中心近两年实施的肝胰十二指肠联合移植2例,1例为酒精性肝硬化伴2型糖尿病,1例为乙肝肝硬化伴2型糖尿病肾病。2例患者均采用原位整块的肝脏、十二指肠、胰腺联合移植。供者器官切取和修整简单,移植时依次吻合肝上、肝下下腔静脉;供者肠系膜上静脉与受者肠系膜上静脉吻合;供者腹腔干动脉与受者肝总动脉吻合。术后采用巴利昔单抗诱导治疗;采用他克莫司(FK506)+霉酚酸酯(MMF)+泼尼松(Pred)三联免疫抑制治疗。结果患者1实施肝胰十二指肠联合移植,术后出现肠瘘,未发生弥漫性腹膜炎和严重感染,经充分引流后,肠瘘逐渐愈合。患者2实施肝胰十二指肠移植联合肾移植,术后出现胰腺周围积液和切口愈合不良,予以充分引流和换药处理后痊愈;2例患者术后移植肝和移植胰腺功能恢复正常,完全脱离胰岛素治疗。患者1由于术后1年7个月发生急性排斥反应,应用甲泼尼龙冲击治疗,出现胃肠穿孔继发腹膜炎而死亡;患者2术后6个月出现血丙氨酸转氨酶(ALT)升至150 U/L,转换为低剂量他克莫司联合西罗莫司治疗,患者肝功能改善,ALT维持在80 U/L。患者存活至今,移植物功能良好。结论对于终末期肝病伴有血糖难以控制的糖尿病患者实施肝胰十二指肠联合移植治疗,可以取得良好的治疗效果。
目的探討肝胰十二指腸聯閤移植的適應證和治療效果。方法總結分析本中心近兩年實施的肝胰十二指腸聯閤移植2例,1例為酒精性肝硬化伴2型糖尿病,1例為乙肝肝硬化伴2型糖尿病腎病。2例患者均採用原位整塊的肝髒、十二指腸、胰腺聯閤移植。供者器官切取和脩整簡單,移植時依次吻閤肝上、肝下下腔靜脈;供者腸繫膜上靜脈與受者腸繫膜上靜脈吻閤;供者腹腔榦動脈與受者肝總動脈吻閤。術後採用巴利昔單抗誘導治療;採用他剋莫司(FK506)+黴酚痠酯(MMF)+潑尼鬆(Pred)三聯免疫抑製治療。結果患者1實施肝胰十二指腸聯閤移植,術後齣現腸瘺,未髮生瀰漫性腹膜炎和嚴重感染,經充分引流後,腸瘺逐漸愈閤。患者2實施肝胰十二指腸移植聯閤腎移植,術後齣現胰腺週圍積液和切口愈閤不良,予以充分引流和換藥處理後痊愈;2例患者術後移植肝和移植胰腺功能恢複正常,完全脫離胰島素治療。患者1由于術後1年7箇月髮生急性排斥反應,應用甲潑尼龍遲擊治療,齣現胃腸穿孔繼髮腹膜炎而死亡;患者2術後6箇月齣現血丙氨痠轉氨酶(ALT)升至150 U/L,轉換為低劑量他剋莫司聯閤西囉莫司治療,患者肝功能改善,ALT維持在80 U/L。患者存活至今,移植物功能良好。結論對于終末期肝病伴有血糖難以控製的糖尿病患者實施肝胰十二指腸聯閤移植治療,可以取得良好的治療效果。
목적탐토간이십이지장연합이식적괄응증화치료효과。방법총결분석본중심근량년실시적간이십이지장연합이식2례,1례위주정성간경화반2형당뇨병,1례위을간간경화반2형당뇨병신병。2례환자균채용원위정괴적간장、십이지장、이선연합이식。공자기관절취화수정간단,이식시의차문합간상、간하하강정맥;공자장계막상정맥여수자장계막상정맥문합;공자복강간동맥여수자간총동맥문합。술후채용파리석단항유도치료;채용타극막사(FK506)+매분산지(MMF)+발니송(Pred)삼련면역억제치료。결과환자1실시간이십이지장연합이식,술후출현장루,미발생미만성복막염화엄중감염,경충분인류후,장루축점유합。환자2실시간이십이지장이식연합신이식,술후출현이선주위적액화절구유합불량,여이충분인류화환약처리후전유;2례환자술후이식간화이식이선공능회복정상,완전탈리이도소치료。환자1유우술후1년7개월발생급성배척반응,응용갑발니룡충격치료,출현위장천공계발복막염이사망;환자2술후6개월출현혈병안산전안매(ALT)승지150 U/L,전환위저제량타극막사연합서라막사치료,환자간공능개선,ALT유지재80 U/L。환자존활지금,이식물공능량호。결론대우종말기간병반유혈당난이공제적당뇨병환자실시간이십이지장연합이식치료,가이취득량호적치료효과。
Objective To investigate the indications and effects of treatment on end-stage liver disease and diabetes mellitus with simultaneous liver-pancreas-duodenum transplantation. Methods In recent 2 years, 2 simultaneous liver-pancreas-duodenum transplantations have been carried out in two patients,one with alcoholic liver cirrhosis and type 2 diabetes mellitus,another one with chronic hepatitis B related liver cirrhosis and type 2 diabetes mellitus. Both of the two patients underwent in situ en bloc liver,duodenum and pancreas transplantation. Organ harvesting and trimming were simple. We anastomosed the suprahepatic inferior vena cava and infrahepatic inferior vena cava of liver graft to the eponymous vessels of recipient,superior mesenteric vein of liver graft was anastomosed to superior mesenteric vein of the recipient; celiac artery of the liver graft was anastomosed to hepatic artery of recipient. Basiliximab was used for induction therapy,tacrolimus(FK506),mycophenolate mofetil(MMF) and prednisone(Pred)were used for immunosuppressive therapy. Results Patient 1 underwent liver-pancreas- <br> duodenum transplantation and suffered post-operative intestinal fistula, which was healed with adequate drainage without diffuse peritonitis and severe infection. Patient 2 underwent combined liver-pancreas-duodenum and kidney transplantation and suffered peripancreatic effusion and surgical wound bad healing which were successfully treated by adequate drainage and changing of wound dressing. The functions of pancreas and liver allograft of these 2 patients were recovered immediately and both patients became insulin-independence postoperatively. Patient 1 suffered an acute rejection episode treated by intravenous bolus methylpredisolone 1 year 7 months after operation, and died of acute peritonitis secondary to gastrointestinal perforation. The level of alanine aminotransferase(ALT)of patient 2 increased to 150 U/L 6 months after transplantation,and immunosuppressive regimen were shifted to low dose tacrolimus and sirolimus therapy,then the ALT level decreased to 80 U/L. Patient 2 is alive with good grafts function. Conclusion It is effective to implement simultaneous liver-pancreas-duodenum transplantation for patients with end-stage liver disease and difficult-to-control diabetes mellitus.